Results 1 to 10 of about 5,501,152 (321)
Cancer Imaging, 2004 Advances in the imaging and treatment of multiple myeloma have occurred over the past decade. This article summarises the current status and highlights how an understanding of both is necessary for optimum management.
S. Vincent Rajkumar, Robert A. Kyle
+14 more sources
New England Journal of Medicine, 2011 Multiple myeloma (MM) is a B cell neoplasm of the bone marrow with a complex array of clinical manifestations including anemia, bone lesions, hypercalcemia, renal dysfunction, and compromised immune function. It accounts for 10%–15% of all hematologic malignancies, and 20% of deaths related to cancers of the blood and bone marrow.
PALUMBO, Antonio, Anderson K.
+9 more sources
Promises and Challenges of Immunogenic Chemotherapy in Multiple Myeloma
Cells, 2022 Immunological tolerance of myeloma cells represents a critical obstacle in achieving long-term disease-free survival for multiple myeloma (MM) patients.
Megan Johnstone +5 more
doaj +1 more source
Frontiers in Oncology, 2022 AimsTo evaluate abnormal metabolites related to treatment response and prognosis of multiple myeloma (MM) patients through ultra performance liquid chromatography tandem mass spectrometry (UPLC-MS).MethodsForty-six symptomatic MM patients were included ...
Yujun Wei +7 more
doaj +1 more source
Blood Cancer Journal, 2022 We here defined the impacts of γ-secretase inhibitors (GSIs) on T-cell-dependent BCMA-specific multiple myeloma (MM) cell lysis and immunomodulatory effects induced by bispecific antibodies (BisAbs).
Hailin Chen +13 more
doaj +1 more source
Cancer Medicine, 2022 Background Maintenance therapy with proteasome inhibitors (PIs) can improve outcomes of multiple myeloma (MM) patients, however, the neurotoxicity and parenteral route of bortezomib limit its long‐term use.
Man Shen +8 more
doaj +1 more source
Journal of the American Academy of Physician Assistants, 2015 This article presents a review of multiple myeloma, precursor states, and related plasma cell disorders. The clinical roles of fluorodeoxyglucose PET/computed tomography (CT) and the potential to improve the management of patients with multiple myeloma are discussed.
Tonon G., Anderson K. C.
+11 more sources
Low NCOR2 levels in multiple myeloma patients drive multidrug resistance via MYC upregulation
Blood Cancer Journal, 2021 MYC upregulation is associated with multidrug refractory disease in patients with multiple myeloma (MM). We, isolated patient-derived MM cells with high MYC expression and discovered that NCOR2 was down-regulated in these cells.
Tomoaki Mori +13 more
doaj +1 more source
Selinexor: Targeting a novel pathway in multiple myeloma
eJHaem, 2023 Selinexor is an orally bioavailable selective inhibitor of nuclear export compound that inhibits exportin‐1 (XPO1), a novel therapeutic target that is overexpressed in multiple myeloma (MM) and is responsible for the transport of ∼220 nuclear proteins to
Clifton C. Mo +9 more
doaj +1 more source
Bone Disease in Multiple Myeloma: Biologic and Clinical Implications
Cells, 2022 Multiple Myeloma (MM) is a hematologic malignancy characterized by the proliferation of monoclonal plasma cells localized within the bone marrow. Bone disease with associated osteolytic lesions is a hallmark of MM and develops in the majority of MM ...
Zachary S. Bernstein +2 more
doaj +1 more source